We
are developing a safer, more effective, and more specific therapy for the
management of neuropathic pain.
Up to 820 million people suffer from neuropathic pain globally, accounting for billions of dollars in healthcare costs. Current treatment options only address symptoms of pain, not the
root cause. That's where we come in.
We are developing SMARTmid™, a DNA plasmid-based drug delivery platform, as a novel, effective, reversible, and long-lasting therapeutic strategy against neuropathic pain.
Nav1.7 is a well-established target to treat pain as it has been shown to play a critical role in the modulation of pain signals, adding credence to our scientific approach.
The global management pain market is expected to reach $110B by 2033. Over the same time period, the market for neuropathic pain is expected to eclipse $13B,
Our technology will not require specialized facilities or equipment for manufacturing and anticipate significantly lower costs than other current gene therapy technologies.
Our Team
Scott Alpizar, PhD
CEO
Daniel Achinko, PhD
CSO
Elton Norman, Esq., CPA
CFO
Anton Dormer, MD, MS
Advisor
Mahesh Narayanan, MS
Advisor
Interested? Contact Us!
We're always looking to connect with investors, collaborators, or other partners! Send us a message!
